X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Torrent Pharma with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs ACTAVIS (US) - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 TORRENT PHARMA   ACTAVIS
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
ACTAVIS
Dec-14
TORRENT PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,76817,418-   
Low Rs1,18610,625-   
Sales per share (Unadj.) Rs346.13,136.6-  
Earnings per share (Unadj.) Rs55.2-391.4-  
Cash flow per share (Unadj.) Rs73.3287.8-  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs257.16,803.1-  
Shares outstanding (eoy) m169.22265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.34.5 95.4%   
Avg P/E ratio x26.8-35.8 -74.7%  
P/CF ratio (eoy) x20.148.7 41.3%  
Price / Book Value ratio x5.72.1 278.7%  
Dividend payout %25.40-   
Avg Mkt Cap Rs m249,8873,728,306 6.7%   
No. of employees `00011.821.6 54.5%   
Total wages/salary Rs m9,9340-   
Avg. sales/employee Rs Th4,971.538,611.5 12.9%   
Avg. wages/employee Rs Th843.20-   
Avg. net profit/employee Rs Th792.4-4,818.3 -16.4%   
INCOME DATA
Net Sales Rs m58,569834,009 7.0%  
Other income Rs m2,233-2,082 -107.3%   
Total revenues Rs m60,802831,927 7.3%   
Gross profit Rs m13,773107,140 12.9%  
Depreciation Rs m3,069180,593 1.7%   
Interest Rs m2,05626,306 7.8%   
Profit before tax Rs m10,881-101,841 -10.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-7,470 0.0%   
Tax Rs m1,545-5,236 -29.5%   
Profit after tax Rs m9,336-104,076 -9.0%  
Gross profit margin %23.512.8 183.0%  
Effective tax rate %14.25.1 276.2%   
Net profit margin %15.9-12.5 -127.7%  
BALANCE SHEET DATA
Current assets Rs m53,841439,416 12.3%   
Current liabilities Rs m31,612320,463 9.9%   
Net working cap to sales %38.014.3 266.1%  
Current ratio x1.71.4 124.2%  
Inventory Days Days9758 167.5%  
Debtors Days Days8466 126.4%  
Net fixed assets Rs m42,079101,841 41.3%   
Share capital Rs m8460-   
"Free" reserves Rs m42,6550-   
Net worth Rs m43,5011,808,934 2.4%   
Long term debt Rs m22,408947,917 2.4%   
Total assets Rs m101,2503,315,181 3.1%  
Interest coverage x6.3-2.9 -219.2%   
Debt to equity ratio x0.50.5 98.3%  
Sales to assets ratio x0.60.3 229.9%   
Return on assets %11.3-2.3 -479.6%  
Return on equity %21.5-5.8 -373.0%  
Return on capital %19.6-3.0 -651.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m14,7620-   
CASH FLOW
From Operations Rs m10,127143,216 7.1%  
From Investments Rs m-7,869-342,913 2.3%  
From Financial Activity Rs m-1,918192,667 -1.0%  
Net Cashflow Rs m212-7,030 -3.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 63.85 Rs / USD

Compare TORRENT PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare TORRENT PHARMA With: SANOFI INDIA  DISHMAN PHARMA  ALKEM LABORATORIES  FULFORD INDIA  PIRAMAL ENTERPRISES  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jan 22, 2018 03:33 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS